Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This randomized controlled trial aims to evaluate the effect of nurse-led telehealth monitoring on medication adherence, self-efficacy, and quality of life in individuals with inflammatory bowel disease (IBD). The study will be conducted at the IBD Outpatient Clinic of Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty. Participants will be randomly assigned to either an intervention group receiving a 3-month structured telehealth program (including education, counseling, phone calls, and reminders) or a control group receiving only standard care and an educational booklet. Outcomes will be assessed at baseline and after 12 weeks.
This randomized controlled trial aims to assess the impact of a nurse-led telehealth monitoring program on medication adherence, self-efficacy, and quality of life in patients with inflammatory bowel disease (IBD). The study will be conducted at the IBD Outpatient Clinic, Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital.
Participants will be randomly assigned to either an intervention or control group. The intervention group will receive a 12-week structured telehealth program including an educational booklet, video content, a Zoom-based group session, biweekly phone calls, and reminder messages. The control group will receive only standard care and the educational booklet, with no additional intervention.
Assessments will be conducted at baseline (Week 0) and at the end of the intervention (Week 12) using validated tools: Harvey-Bradshaw Index (HBI), Simple Clinical Colitis Activity Index (SCCAI), Medication Adherence Report Scale (MARS), MedTake Test, IBD Self-Efficacy Scale, IBD Quality of Life Questionnaire, and IBD Distress Scale.
The effectiveness of the intervention will be determined by comparing pre- and post-intervention outcomes between the two groups.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention Group | Experimental | Participants in the intervention group will be included in a structured telehealth monitoring program led by a nurse for 12 weeks. |
|
| Control group | Other | Participants in the control group will only receive standard care. No additional interventions will be implemented during the 12-week period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nurse-led Telehealth Monitoring Program | Behavioral | Participants in the intervention group will be included in a structured telehealth monitoring program led by a nurse for 12 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Medication Adherence Report Scale (MARS) scores | This scale assesses self-reported medication adherence behavior. The outcome will evaluate the change in MARS scores from baseline to week 12 to determine the impact of the telehealth intervention on adherence. | Baseline (Week 0) and 12 weeks (3 months) following telehealth monitoring. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in MedTake Test scores | The MedTake test evaluates patients' ability to understand and manage their oral medication regimen. This outcome will examine improvements in medication-taking skills from baseline to the end of the 12-week intervention. | Baseline (Week 0) and 12 weeks (3 months) following telehealth monitoring. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kimya Kılıçaslan, PhD Candidate | Contact | +90 535 083 45 53 | kimya.kilicaslan@iuc.edu.tr | |
| Zeliha Tulek, PhD, Prof. | Contact | +90 532 776 29 93 | ztulek@iuc.edu.tr |
| Name | Affiliation | Role |
|---|---|---|
| Kimya Kılıçaslan, PhD Candidate | Istanbul University - Cerrahpasa Institute of Graudate Studies | Principal Investigator |
| Zeliha Tulek, PhD, Prof. | Istanbul University - Cerrahpasa, Florence Nightingale Faculty of Nursing |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Istanbul University - Cerrahpasa Cerrahpaşa Faculty of Medicine Department of Gastroenterology | Recruiting | Istanbul | 34098 | Turkey (Türkiye) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37140025 | Result | Gordon M, Sinopoulou V, Lakunina S, Gjuladin-Hellon T, Bracewell K, Akobeng AK. Remote care through telehealth for people with inflammatory bowel disease. Cochrane Database Syst Rev. 2023 May 4;5(5):CD014821. doi: 10.1002/14651858.CD014821.pub2. | |
| 35323120 | Result | Pang L, Liu H, Liu Z, Tan J, Zhou LY, Qiu Y, Lin X, He J, Li X, Lin S, Ghosh S, Mao R, Chen M. Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Med Internet Res. 2022 Mar 24;24(3):e28978. doi: 10.2196/28978. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study is designed as a randomized controlled trial with a pretest-posttest design, consisting of two groups: an intervention group and a control group.
Not provided
Not provided
Single
| No intervention | Other | Participants in the control group will only receive standard care. No additional interventions will be implemented during the 12-week period. |
|
| Change in Harvey-Bradshaw Index scores (for Crohn's Disease) and Change in Simple Clinical Colitis Activity Index scores (for Ulcerative Colitis) |
These indices measure disease activity in Crohn's Disease and Ulcerative Colitis, respectively. The outcome will track changes in disease activity from baseline to week 12 following the telehealth monitoring. |
| Baseline (Week 0) and 12 weeks (3 months) following telehealth monitoring |
| Change in Inflammatory Bowel Disease (IBD) Self-Efficacy Scale scores | This scale measures a patient's confidence in managing their IBD-related health challenges. The outcome will assess changes in self-efficacy levels between baseline and week 12. | Baseline (Week 0) and 12 weeks (3 months) following telehealth monitoring. |
| Change in Inflammatory Bowel Disease Questionnaire scores | This questionnaire evaluates the quality of life in patients with IBD. The outcome will assess the effect of the intervention on quality of life by comparing scores at baseline and after 12 weeks. | Baseline (Week 0) and 12 weeks (3 months) following telehealth monitoring. |
| Aykut Ferhat Çelik, MD, Prof. | Istanbul University - Cerrahpasa Cerrahpaşa Faculty of Medicine Department of Gastroenterology | Study Chair |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D055118 | Medication Adherence |
| D003093 | Colitis, Ulcerative |
| ID | Term |
|---|---|
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
| D010349 | Patient Compliance |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |
| D003092 | Colitis |
| D003108 | Colonic Diseases |
Not provided
Not provided